FGF-21 is a therapeutic option for chronic metabolic diseases such as NASH and diabetes (Gaich et al., 2013; Talukdar et al., 2016; Geng et al., 2020; Zarei et al., 2020; Talukdar and Kharitonenkov, 2021). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.